A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for ARDS secondary to COVID-19
Oliver J. McElvaney, Natalie McEvoy, Fiona Boland, Oisín F. McElvaney, Grace Hogan, Karen Donnelly, Oisín Friel, Emmet Browne, D. Fraughen, Mark P. Murphy, Jennifer Clarke, Orna Ní Choileáin, Eoin O’Connor, Rory McGuinness, Maria Boylan, Alan L. Kelly, John Hayden, Ann M. Collins, Ailbhe Cullen, Deirdre Hyland, Tomás P. Carroll, Pierce Geoghegan, John G. Laffey, Martina Hennessy, Ignacio Martín‐Loeches, Noel G. McElvaney, Gerard F. Curley
Topics & Concepts
ARDSPlaceboMedicineCoronavirus disease 2019 (COVID-19)Double blindRandomized controlled trialAlpha (finance)AnesthesiaInternal medicineLungSurgeryPathologyDiseasePatient satisfactionInfectious disease (medical specialty)Construct validityAlternative medicineCOVID-19 Clinical Research StudiesProtease and Inhibitor MechanismsSARS-CoV-2 and COVID-19 Research